منابع مشابه
Biomarker efficacy in multiple sclerosis diagnosis and treatment
The goal in studies concerning biomarkers in autoimmune diseases is finding a marker which fluctuates in correlation with the disease’s severity and settles within normal borders after effective treatment. This marker would later be used as an efficient tool in diagnosis and analysis of medicine clout. It seems the most cogent biomarkers are those measurable in serum or plasma. MS is a neurolog...
متن کاملTumefactive: A Rare First presentation of Multiple Sclerosis
Tumefactive demyelinating lesions are a rare presentation of multiple sclerosis (MS). Diagnosis of tumefactive is commonly carried out using magnetic resonance image (MRI). Tumefactive diagnosis is difficult because of may similar to the clinical and MRI characteristics of glioma or a cerebral abscess. We presented a 35-years-old female with one episode of secondary generalized seizure after de...
متن کاملPediatric multiple sclerosis: Conventional first-line treatment and general management.
Many disease-modifying therapies are currently available for adults with relapsing-remitting multiple sclerosis (MS) but none of them has been tested in pediatric MS in randomized placebo-controlled trials. At present, as suggested by observational studies and experts' guidelines, interferon-β and glatiramer acetate continue to be the standard first-line treatments for pediatric MS. Observation...
متن کاملMultiple Sclerosis in Iran
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS). This highlydisabling disorder is characterized by a variable clinical course. MS is a heterogeneous disease with acomplex pathology and significant social and economic impact. MS is associated with dysfunction ofparts of the nervous system which results in a range of signs and symptoms, ...
متن کامل[Natalizumab treatment in multiple sclerosis].
Multiple sclerosis is a neurodegenerative and inflammatory immune disorder in the central nervous system (CNS). Most patients show relapse-remitting clinical course. Some disease modifying medications for preventing the relapses including natalizumab (NTZ) are approved in Japan. Natalizumab (NTZ), a monoclonal antibody against α4 integrin present on the surface of lymphocytes, inhibits the bind...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revue Neurologique
سال: 2021
ISSN: 0035-3787
DOI: 10.1016/j.neurol.2020.05.014